CareDx Inc. revises revenue guidance for the full year ended December 31, 2023. For the period, the company expects revenue to be in the range of $279 million to $280 million, which is above the high end of guidance for fiscal year 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.36 USD | +2.69% | -16.19% | +11.33% |
May. 30 | CareDx, Inc Announces New Data to Be Presented At the 2024 American Transplant Congress | CI |
May. 17 | Craig-Hallum Adjusts Price Target on CareDx to $22 From $15, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.33% | 678M | |
-39.42% | 8.39B | |
+1.33% | 3.32B | |
+2.95% | 2.48B | |
-19.81% | 2.06B | |
-23.12% | 1.59B | |
+33.59% | 1.15B | |
-7.21% | 704M | |
-32.45% | 508M | |
-6.86% | 273M |
- Stock Market
- Equities
- CDNA Stock
- News CareDx, Inc
- CareDx, Inc Revises Revenue Guidance for the Full Year Ended December 31, 2023